Objective: To identify the real number of hyperhomocysteinemic Alzheimer's patients who may benefit from homocysteine-lowering therapy.
Methods: Basal and post-methionine load homocysteine levels were assessed by rp-HPLC system.
Results: PML test revealed twice as many hyperhomocysteinemic AD subjects with respect to the fasting analysis.